RxDoctor Payments Data

Leslie Garcia Rivera, MD

General Practice · Orlando, FLNPI 1578773271

Payments from drug & device makers

$939in general payments, 2019–2025

Across 24 payments — averaging $39.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$244
  • GSK$163
  • Novo Nordisk$146
  • Cequr Corporation$137
  • Abbott$111
  • Exact Sciences$66
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$939 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$5,667
Medicare patients
21
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$96,460
JardianceEmpagliflozin65$80,775
EliquisApixaban59$67,422
TrulicityDulaglutide34$64,683
JanuviaSitagliptin Phosphate45$48,591
FarxigaDapagliflozin Propanediol36$42,594
LinzessLinaclotide43$29,057
TradjentaLinagliptin18$20,616
XareltoRivaroxaban12$15,701
Ondansetron Hcl32$12,379
Tresiba Flextouch U-100Insulin Degludec16$9,440
EntrestoSacubitril/Valsartan12$8,469
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,306
Atorvastatin Calcium621$5,642
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$25$101,39183 claims
Novo NordiskOzempic$146$96,46066 claims
AstraZenecaFarxiga$244$42,59436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →